Galectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2025 and Provides Business Update

Core Insights - Galectin Therapeutics, Inc. reported financial results and business updates for the second quarter and first half of 2025, highlighting progress in its NAVIGATE trial for belapectin, a treatment for MASH cirrhosis [1][2]. Financial Performance - As of June 30, 2025, the company had cash and cash equivalents of $13.8 million and a new $10 million line of credit to fund operations through mid-2026 [9]. - Research and development expenses for Q2 2025 were $3.3 million, a decrease from $9.8 million in Q2 2024, primarily due to the timing of expenditures related to the NAVIGATE trial [9]. - General and administrative expenses for Q2 2025 were $1.4 million, slightly down from $1.5 million in the same period last year [9]. - The net loss applicable to common stockholders for Q2 2025 was $7.6 million, or ($0.12) per share, compared to a net loss of $12.4 million, or ($0.20) per share for Q1 2024 [9][11]. Clinical Development - The NAVIGATE trial data indicates that belapectin shows a clinically significant response in Fibroscan® results, supporting its primary endpoint of preventing esophageal varices after 18 months of treatment [2][4]. - The 18-month analysis demonstrated a lower incidence of liver stiffness progression and varices in the belapectin 2 mg arm compared to placebo, suggesting its potential to modify disease progression in patients with MASH cirrhosis [3][4]. - The updated analysis confirmed that the effects of belapectin were maintained in patients who continued treatment into the second 18-month period, reinforcing its efficacy [4][5]. Strategic Initiatives - The company is focused on engaging with the U.S. Food and Drug Administration to discuss potential next steps for the belapectin program and is exploring strategic partnership opportunities [2][3]. - A KOL event in June featured discussions on the NAVIGATE trial results and the treatment landscape for MASH cirrhosis, indicating ongoing efforts to raise awareness and support for the treatment [4]. Market Position - Galectin Therapeutics aims to address the significant unmet medical need for patients with MASH-associated liver cirrhosis and portal hypertension, positioning belapectin as a potential new treatment option [3][4]. - The company is also developing additional programs for cancer treatment, indicating a broader therapeutic focus [7].